EA202090712A1 - NEW GENETIC ENGINEERED T-CELL RECEPTORS AND IMMUNE THERAPY WITH THEIR USE - Google Patents

NEW GENETIC ENGINEERED T-CELL RECEPTORS AND IMMUNE THERAPY WITH THEIR USE

Info

Publication number
EA202090712A1
EA202090712A1 EA202090712A EA202090712A EA202090712A1 EA 202090712 A1 EA202090712 A1 EA 202090712A1 EA 202090712 A EA202090712 A EA 202090712A EA 202090712 A EA202090712 A EA 202090712A EA 202090712 A1 EA202090712 A1 EA 202090712A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen
col6a3
tcr
cell receptors
new genetic
Prior art date
Application number
EA202090712A
Other languages
Russian (ru)
Inventor
Феликс Ундердорбен
Себастиан Бунк
Мартин Хофманн
Майке Хутт
Доминик Маурер
Леони Алтен
Клаудиа Вагнер
Original Assignee
Имматикс Байотекнолоджиз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имматикс Байотекнолоджиз Гмбх filed Critical Имматикс Байотекнолоджиз Гмбх
Priority claimed from PCT/EP2018/080176 external-priority patent/WO2019086665A1/en
Publication of EA202090712A1 publication Critical patent/EA202090712A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к антигенраспознающим структурам к антигенам COL6A3. В частности, в изобретении предложены новые полученные методами генной инженерии молекулы на основе Т-клеточного рецептора (ТКР), являющиеся селективными и специфическими для экспрессируемого опухолями антигена COL6A3. ТКР по изобретению и фрагменты, связывающиеся с антигеном COL6A3, образованные из этого ТКР, полезны для диагностики, лечения и профилактики раковых заболеваний, при которых экспрессируется COL6A3. Предложены также нуклеиновые кислоты, кодирующие антигенраспознающие структуры по изобретению, векторы, включающие данные нуклеиновые кислоты, рекомбинантные клетки, экспрессирующие эти антигенраспознающие структуры, и фармацевтические композиции, включающие соединения по изобретению.The present invention relates to antigen recognition structures for COL6A3 antigens. In particular, the invention provides new genetically engineered T-cell receptor (TCR) molecules that are selective and specific for the tumor-expressed COL6A3 antigen. The TCR of the invention and the fragments that bind to the COL6A3 antigen derived from this TCR are useful for the diagnosis, treatment and prevention of cancers in which COL6A3 is expressed. Also provided are nucleic acids encoding antigen-recognition structures according to the invention, vectors including these nucleic acids, recombinant cells expressing these antigen-recognition structures, and pharmaceutical compositions comprising compounds of the invention.

EA202090712A 2017-11-06 2018-11-05 NEW GENETIC ENGINEERED T-CELL RECEPTORS AND IMMUNE THERAPY WITH THEIR USE EA202090712A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582202P 2017-11-06 2017-11-06
PCT/EP2018/080176 WO2019086665A1 (en) 2017-11-06 2018-11-05 Novel engineered t cell receptors and immune therapy using the same

Publications (1)

Publication Number Publication Date
EA202090712A1 true EA202090712A1 (en) 2020-07-24

Family

ID=71833546

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090712A EA202090712A1 (en) 2017-11-06 2018-11-05 NEW GENETIC ENGINEERED T-CELL RECEPTORS AND IMMUNE THERAPY WITH THEIR USE

Country Status (1)

Country Link
EA (1) EA202090712A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693676A (en) * 2022-02-28 2023-09-05 东莞市朋志生物科技有限公司 Anti-mycoplasma pneumoniae antibody, reagent for detecting mycoplasma pneumoniae and kit

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693676A (en) * 2022-02-28 2023-09-05 东莞市朋志生物科技有限公司 Anti-mycoplasma pneumoniae antibody, reagent for detecting mycoplasma pneumoniae and kit
CN116693676B (en) * 2022-02-28 2024-04-05 东莞市朋志生物科技有限公司 Anti-mycoplasma pneumoniae antibody, reagent for detecting mycoplasma pneumoniae and kit

Similar Documents

Publication Publication Date Title
PH12020550600A1 (en) Novel engineered t cell receptors and immune therapy using the same
MX2022015821A (en) Novel t cell receptors and immune therapy using the same.
MX2019001769A (en) T cell receptors and immune therapy using the same.
MX2019006724A (en) Novel t cell receptors and immune therapy using the same.
MX2023003463A (en) T cell receptors and immune therapy using the same against prame positive cancers.
WO2018172533A3 (en) T cell receptors and immune therapy using the same against prame positive cancers
PH12019500312A1 (en) T cell receptors and immune therapy using the same
MX2019006727A (en) Novel t cell receptors and immune therapy using the same.
CR20190594A (en) Novel t cell receptors and immune therapy using the same
MX2020001996A (en) Anti-cd137 molecules and use thereof.
EA201792484A1 (en) NEW CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE OF MYELOMA AND OTHER CANCER IN IMMUNOTHERAPY
EA201791853A1 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE APPLICATION IN THE IMMUNOTHERAPY OF CANCER OF THE REFERRAL GLAND AND OTHER TYPES OF CANCER
EA201791925A1 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE APPLICATION IN IMMUNOTHERAPY OF SEVERAL TUMOR SPECIES
EA202090712A1 (en) NEW GENETIC ENGINEERED T-CELL RECEPTORS AND IMMUNE THERAPY WITH THEIR USE
EA201990488A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
EA201992002A1 (en) T-CELL RECEPTORS AND IMMUNE THERAPY OF PRAME-POSITIVE CANCER DISEASES WITH THEIR APPLICATION
EA201991139A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
EA201991151A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
MY195101A (en) Novel T Cell Receptors and Immune Therapy Using the Same
EA201992583A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
PH12019501263A1 (en) Novel t cell receptors and immune therapy using the same
AR113834A1 (en) GENETICALLY MODIFIED T-CELL RECEPTORS AND IMMUNE THERAPIES THAT USE THEM